The efficiency of fractionated parenteral iron treatment in CAPD patients
| Autor: | F, Akcicek, M, Ozkahya, M, Cirit, E, Ok, A, Unsal, H, Toz, A, Celik, G, Atabay, A, Basci |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Adult
Ferric Oxide Saccharated Male Sucrose Transferrin Anemia Middle Aged Ferric Compounds Drug Administration Schedule Recombinant Proteins Glucaric Acid Hematocrit Peritoneal Dialysis Continuous Ambulatory Organization and Administration Ferritins Injections Intravenous Humans Kidney Failure Chronic Drug Therapy Combination Female Erythropoietin |
| Zdroj: | Advances in peritoneal dialysis. Conference on Peritoneal Dialysis. 13 |
| ISSN: | 1197-8554 |
| Popis: | Some chronic renal failure patients respond poorly to recombinant human erythropoietin (rHuEPO). In continuous ambulatory peritoneal dialysis (CAPD) patients, such a poor response may indicate inadequate dialysis or low body iron stores. To correct iron deficiency, once-a-week intravenous iron supplementation is recommended. However, hemodialysis patients receive iron supplements three times a week. This study was designed to compare the efficacy of iron supplementation between once-weekly and twice-weekly regimens. In both groups, rHuEPO doses were similar. Seventeen CAPD patients were studied. All had hemoglobin levels less than 10 g/dL. Ten patients were given 100 mg intravenous iron once weekly, and 7 were given 50 mg intravenous iron twice weekly until a total iron dose of 600 mg was achieved (stage I). The patients were crossed over to receive another 600 mg iron (stage II). Hematocrit increased significantly in patients receiving twice-a-week iron supplementation (+3.8% and 6%) compared to those receiving once-a-week iron supplementation (+1.3% and 1.4%) during stages I and II. The ferritin levels were not different between the groups. In conclusion, rHuEPO is more effective when administered with intravenous iron. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|